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Aim: Co-infection in HIV-1 patients withMycobacterium tuberculosis poses considerable risk of developing
the immune reconstitution inflammatory syndrome (IRIS), especially upon the initiation of antiretroviral
therapy (ART). Methodology & results: For transcriptomic analysis, peripheral blood mononuclear cells’
whole gene expressionwas used from three patient groups: HIV+ (H), HIV-TB+ (HT), HIV-TB+ with IRIS (HTI).
Pathway enrichment and functional analysis was performed before and after highly active ART. Genes in
the interferon-stimulating and ZNF families maintained tight functional interaction and tilted the balance
in favor of TB-IRIS. Discussion & conclusion: The functional impairment of interaction between ZNF genes
and interferon-stimulated genes, along with higher expression of S100A8/S100A9 genes possibly forms
the genomic basis of TB-IRIS in a subset of HIV patients while on highly active ART.
First draft submitted: 18 Oct 2017; Accepted for publication: 21 Feb 2018; Published online: 09 Jul 2018
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AIDS was first diagnosed in 1981, and is caused by HIV [1]. HIV and TB constitute the main burden of infectious
disease in poor countries. In the human host, Mycobacterium tuberculosis (MTB) and HIV are able to potentiate
one another, thereby facilitating the deterioration of immunological functions. Therefore, coinfection in HIV-1
patients with other pathogens (viral and fungal) including MTB poses considerable risk of developing the immune
reconstitution inflammatory syndrome (IRIS), especially upon the initiation of antiretroviral therapy (ART). This
is usually characterized by clinical progression of a therapeutically treated condition leading to inflammation and
other clinical modalities, the hallmark of which is compromised immune system [2]. MTB is one of the most
common pathogens associated with IRIS resulting into TB-IRIS [3,4], which is to related fatal co-morbidities.
The proportion of knownHIV-positive TB patients on ART was 85% globally [5], and it is noteworthy that more
than 30% of those coinfected patients develop the active disease faster than people with HIV infection alone [6].
Currently, the most effective therapy for treating HIV infection is highly active antiretroviral therapy (HAART) [7].
In about 10–32% of AIDS patients, HAART causes severe side effects resulting into IRIS [8].
Although the TB-IRIS was first reported in the early 1990s [9], its overall incidence and underlyingmechanisms in
immunopathogenesis remain unclear, and appear to be result of unbalanced reconstitution of effector and regulatory
T-cells, leading to exuberant inflammatory response in patients who are on HAART. Expansion of TB antigen-
specific IFN-γ producing peripheral T-helper cells are generally associated with hyperinflammation in TB-IRIS [10],
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but this expansion is not seen in all TB-IRIS cases suggesting that the associationmight not be the cause [11]. Current
studies have mainly focused on the components of the immune system, such as mycobacterial-specific T cells [10,12],
but the findings are often confusing and inconsistent between different study populations, especially as in the
case of purified protein derivative-specific T cells [10,11]. Contribution of innate immunity to IRIS is well known,
along with the presence of inflammatory cells (CD68+ macrophages) [11], enhanced natural killer cell activation
and degranulation activity [13,14], increased neutrophil counts in the cerebrospinal fluid [15] of TB-meningitis-IRIS
and elevated levels of IL-6 and C-reactive protein in both Mycobacterium avium-associated IRIS and paradoxical
TB-IRIS [16]. Moreover, the TB-IRIS patients also show elevated expression of pattern recognition receptors such
as Toll-like receptor 2 (TLR2) [17]. In monocytes, isolated from HIV-TB coinfected patients, a microarray study
has shown evidence of imbalance between the complement effector C1q and the inhibitor C1-INH in those who
developed TB-IRIS [18]. Currently, despite a plethora of studies on HIV-TB IRIS, no biomarkers for TB-IRIS have
been identified and the underlying genomic basis of HIV-TB-IRIS remains to be elucidated. Furthermore, IRIS has
not been delineated at the level of complete human genomes. In this context, and notwithstanding previous research
efforts, it is important to iterate that the previous microarray-based studies on macrophages [19] provided limited
coverage in comparison to the in-depth coverage with the next-generation sequencing shown in our study. How
the next-gene sequencing overcomes the limitations imposed by microarray are discussed by Hurd and Nelson [20].
In this study, through genome-wide study, we have compared TB-IRIS and non-TB-IRIS groups to find genomic
modalities that can serve as potential biomarkers for TB-IRIS, along with explaining the underlying mechanisms.
Through differentially expressed gene comparisons [21] and pathway enrichment analysis, we have identified key
genes related to HIV-TB-IRIS and proposed a hypothetical model to illustrate the possible underlying genomic
basis that explains the occurrence of HIV–TB-associated IRIS in coinfected patients.With the development of next-
generation sequencing genomic technologies, the genome-wide transcriptome profiling provides holistic approach
in gathering genomic information on the status of the immune system, disease development and in visualizing
genes involved in these processes [22].
Methods
Sample collection, the peripheral blood mononuclear cell RNA extraction & RNA-seq
All participants were screened for HIV antigens and antibodies via standard ELISA analyses, and these findings were
further confirmed by western blotting. CD4+ T-cell counts were obtained by flow cytometry, and the viral loads
were measured by real-time quantitative PCR (RT-qPCR). HIV serum-positive patients were also diagnosed for
MTB, as assessed by microbiology tests (acid fast bacilli stain, cultures on Lowenstein–Jensen media or GeneXpert
PCR), more details are described in Table 1. All clinical tests mentioned above were performed by the Hospital’s
Clinical Laboratory, which has a certified license issued by the National AIDS Reference Laboratory in PR China
Center for Disease Control and Prevention. Treatment for the diagnosed HIV-TB patients consisted of standard
fixed-dose chemotherapy for 2 weeks with isoniazid (H), ethambutol (E), rifampicin (R) and pyrazinamide (Z),
followed by a combination of HAART and anti-TB treatment (HERZ) [23]. The HAART regimen consisted
of Zidovudine plus Lamivudine with Efavirenz, which is the recommended anti-HIV treatment regimen in PR
China [24]. None of the patients were treated with HAART before, and there was no evidence of co-infection with
hepatitis B or C virus, cytomegalovirus, syphilis, toxoplasma. The criteria for TB-associated IRIS was defined and
classified according to the consensus adult TB-IRIS case definition developed by the International Network for
Study of HIV-associated IRIS [25]. More details are shown in Table 2.
32 blood samples (5 ml per patient/sample) from 16 participants recruited at the Shenzhen Third People’s
Hospital from April 2013 to September 2013 were collected. The peripheral blood mononuclear cells (PBMCs)
were isolated immediately from the whole blood before, and 2 weeks after the initiation of HAART. The total
RNA was extracted from the fresh PBMCs using the Qiagen RNeasy kit (Qiagen, Shanghai, PR China). The
mRNAs were purified using oligo(dT) beads then used to construct RNA-seq libraries, which were sequenced
on an Illumina HiSeq 2000 sequencing platform (using TruSeqV3 sequencing reagents) at the Beijing Genomics
Institute, Shenzhen, PR China (Expected library size: 200 bp; read length: 100 nt and sequencing strategy:
paired-end sequencing) as previously described [26].
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Table 2. Diagnosis of paradoxical TB related immune reconstitution inflammatory syndrome.
Patient (A) Antecedent requirements (B) Clinical criteria (C) Alternative explanations
Diagnosis of TB TB treatment
before ART
(weeks)
Response to TB
treatment
Major Minor Other
opportunistic
infection
Drug adverse
reaction
HTI 0 Definitive 2 + Worsening
radiological
Fever and
worsening
respiratory
symptoms
− −
HTI 1 Definitive 2 + Worsening
radiological and
enlarging lymph
nodes
Fever − −
HTI 2 Definitive 2 + Worsening
radiological
Fever and
worsening
respiratory
symptoms
− −
HTI 3 Definitive 2 + Worsening
radiological and
enlarging lymph
nodes
Fever and
worsening
respiratory
symptoms
− −
HTI 4 Definitive 2 + Worsening
radiological
Fever and
worsening
respiratory
symptoms
− −
HTI 5 Definitive 2 + New and enlarging
lymph nodes
Fever − −
According to consensus case definition published in 2008 [25].
ART: Antiretroviral therapy; HTI: HIV-TB+ with IRIS; IRIS: Immune reconstitution inflammatory syndrome.
Table 3. Patient groups and changes in the number of CD4+ T cells and HIV plasma RNA load before and after highly
active antiretroviral therapy treatment.
Group CD4 (cells/μl) HIV RNA load (copies/ml)
Before HAART HAART 2 weeks later Before HAART HAART 2 weeks later
TB-IRIS (HTI) 62.5 ± 46.4† 190.3 ± 127.3 3.86 ± 3.6 × 106† 2.78 ± 5.14 × 104
TB-non-IRIS (HT) 249 ± 120.3 330 ± 134.8 6.76 ± 11.1 × 106 500 ± 0
HIV-non-IRIS (H) 235 ± 117.6 334.5 ± 111.5 1.97 ± 1.74 × 105 500 ± 0
†Before HAART, the CD4+ T-cell count was lower in the HTI group (HTI vs [HT+ H], p-value = 0.010,Wilcoxon Rank Sum Test), the HIV-RNA load was higher (HTI vs [HT+ H], p-value = 0.023,
Wilcoxon Rank Sum Test) in HTI group.
H: HIV+; HAART: Highly active antiretroviral therapy; HT: HIV-TB+; HTI: HIV-TB+ with IRIS; IRIS: Immune reconstitution inflammatory syndrome.
Table 4. Functional domain enrichment using targetmine.
Protein domain p-value ZNF genes rate (%) Interpro ID
Zinc finger C2H2-type/integrase
DNA-binding domain
3.08 × 10-11 91.84 IPR013087
Zinc finger, C2H2 2.08 × 10-10 88.24 IPR007087
Zinc finger, C2H2-like 2.77 × 10-10 88.46 IPR015880
Krueppel-associated box 7.96 × 10-10 97.06 IPR001909
Results depicting the functional domain enrichment of 392 DE genes. The p-value was calculated using the hypergeometric distribution and correction by the Holm-Bonferroni (H-B)
method.
Analysis pipeline
Genome-wide transcriptome data from the PBMCs from four HIV+ patients, six HIV+/TB+ patients and six
HIV+/TB+/IRIS patients before and after HAART (four H, six HT and six HTI, Table 3) were analyzed using
Illumina Hiseq 2000. 32 pair-ends RNA-seq data were produced, with the data volume up to 185 GB.
Pairwise comparisons were carried out for before and after HAART time points for: HT group, HTI group
and HT and HTI groups, respectively (Supplementary Figure 4). Differentially expressed genes (DEGs) with
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p-value < 0.05, q-value < 0.05 and |Log2 (fold change) | > 1 were identified for each comparison. DEGs in
different groups were then uploaded to an online website TargetMine [27] for the pathway analysis. The results were
then used for association analysis, and other downstream analyses (Supplementary Figure 4).
Analysis of DEGs
The recommended pipeline of Cufflinks version 2.2.1 [21] was used, with the default parameters set. If six biological
replicates are used, the empirical true positive rate of Cuffdiff2 could reach over 85% by adjusting the parameters
set, but the empirical false-positive rate still existed [28]. Considering this, Kruskal–Wallis (K–W) significance test
among three groups was used in filtering out the false-positive rate. All the values for gene expression were exported
as Fragments per kilobase million (FPKM); Reference genome and gene transfer files (GTFs) were from iGenomes
UCSC hg19 gene annotation. Sequence alignments were conducted by using TopHat version 2.0.14 [29].
The DEGs were selected from three groups: HIV-TB group and HIV-TB-IRIS group at pre- and post-HAART
stages; HIV-TB group before and after HAART initiation; HIV-TB-IRIS group before and after HAART. No DE
genes were detected in analysis of HIV group before and after HAART. The software Cuffdiff2 integrated in the
Cufflinks packages was used to find DEGs, with a threshold value (p-value < 0.05, q-value < 0.05 and |Log2
(Fold-change) > 1|) set. Considering the additional influence of TB infection, the FPKM values were extracted
from the DEGs selected in group-1). With the FPKM values of HIV group added in, K–W significance test was
conducted among three groups. The threshold values were set as p-value< 0.01, FDR (false discovery rate)< 0.05.
The selected genes were then used for pathway analysis.
Enrichment analysis
Enrichment analysis was performed using online website TargetMine [27]. TargetMine pathway analysis compiled
KEGG pathway and Reactome database as sources. The p-values were calculated by the statistical tools embedded
in the online platforms used for analysis herein [27]. The results were filtered by a cutoff adjusted p-value of 0.05
and in order to select functionally significant candidate pathways.
Gene set enrichment analysis (GSEA) was conducted by GSEA [30] with Reactome v5.0 as database. The gene
set was set as the method to permute parameters set as default. Nominal p-value < 0.01 and FDR < 0.05 were
used as standard filters.
Correlation analysis
Correlation analysis was performed among the enriched genes and HIV load (before and after HAART) by using
Spearman Correlation Coefficient in HIV, HIV-TB, HIV-TB-IRIS groups. The results were used for showing
whether the enriched genes were significantly correlated with the biological processes and for further explaining the
underlying mechanisms.
RT-qPCR validation
Before RT-qPCR, primers were designed using the online tools Primer-BLAST [31] in NCBI (National Center
for Biotechnology Information: www.ncbi.nlm.nih.gov/). We selected eight highly expressed genes (genes and the
corresponding primers used are listed in Supplementary Table 12) in our candidate DEG sets. A reference gene,
β-Actinwas used in quantifying the gene expression levels. In addition, we selected three, six and one genes from the
HTI, HT and H groups, respectively, as templates for the RT-qPCR. Reverse transcription of the candidate RNA
sample was performed using the 1st strand cDNA Synthesis kit (Takara). Expression levels were measured with
the Step One Plus instrument, according to the standard protocol recommended by the manufacturer (Applied
Biosystems, Shanghai, PR China). The relative expression levels of PBMC RNA among the three groups were
calculated by the 2-Ct method normalized by β-Actin gene.
Results
Clinical comparisons & RNA-seq
Up until now, there is no gold standard for the diagnosis of IRIS, which is mainly based on clinical indices, such
as base line CD4+ T-cell counts (<100/μl), deterioration of the condition after the initiation of HAART, and the
degree of plasma viremia [4]. In the clinical samples collected, we found that before the initiation of HAART the
CD4+ T-cell counts were lower (group HTI vs [HT + H], p-value = 0.010, Wilcoxon Rank Sum Test, Wilcox.test
in software R package, with the alternative = less, paired = FALSE), coinciding with higher HIV RNA load (group
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HTI vs [HT + H], p-value = 0.023, Wilcoxon Rank Sum Test, Wilcox.test in software R package, with the
alternative = less, paired = FALSE) in the IRIS group than that in non-IRIS groups (Table 3). Following HAART
in the HTI group, the CD4+ T-cell counts presented a certain degree of comeback concomitant with only slightly
decreased HIV-RNA load (Table 3), and with different changes in different groups, implying that there possibly
exists an essential biological and genomic distinction between H, HT and HTI groups. Although there were some
intragroup differences, more intergroup differences were apparent.
In all 32 samples (16 subjects were studied at pre- and 2 weeks post-HAART time points, four with HIV only,
six with HIV and TB without IRIS, and six with HIV and TB who developed IRIS), the RNA-seq data derived
from the three groups were mapped to human reference genome, with the average base read of 29 million. The
average mapping rate of all samples was 92.52%, whereas the average mapping rates (Supplementary Table 1)
of each group were 92.23% (HTI), 92.61% (H) and 92.81% (HT), respectively. Principal component analysis
(PCA) was performed on all samples and FPKM values were assessed for each sample before HAART, which
distinguished HTI group from the other two groups on PC1 (Figure 1A & B). While the HTI group completely
and independently segregated toward the right before HAART from the H and HT groups (Figure 1A), further
suggesting the possibility of special biological and gene traits unique to HTI group as discussed before.
Interestingly, following HAART the HT and H groups appeared to show some overlaps with the HTI group
(Figure 1B), suggesting that some changes were common, along with some specific differences in the HTI group
in comparison to other two groups analyzed pre- and post-HAART in this study. Furthermore, the multigroup
PCA analysis combining all pre- and post-HAART samples for the three groups confirmed the distinctness of the
HTI group both before and after HAART, with limited crossover in relationship between HTI and HT groups
following HAART. This PC analysis also implies the genetic stability of the groups, which is highly critical in
making functional assumptions and clinical correlations (Supplementary Figure 1A).
To address these observations of the PCA (Figure 1B), we examined the nature of overlapping DEGs between
groups before HAART (Figure 1E), and after HAART (Figure 1F). There were 45 genes that overlapped between
three groups after HAART (Figure 1F), 13 of which also overlapped before HAART (Figure 1E) and 32 following
HAART between the three groups. FollowingHAART, the nature of the overlapping genes changed, andmost genes
(17 of 32 genes – 53%) were focused in functions associated with cell integrity, chromatin, spindle formation, cell
proliferation, nucleolar, kinetochore, DNA replication/metabolism and checkpoint functions, G-coupled receptors,
microtubule and cell integrins, and so on, which are in sharp contrast with the overlapping genes before HAART
that varied considerably in functional annotation, with only some associating with cellular integrity (Supplementary
Table 2).
Significant differential expression of ZNF genes in different groups before HAART
For the comparison HT versus the HTI group (intergroup), before HAART, 947 DEGs were identified using
Cuffdiff2 tools of Cufflinks packages v2.2.1 with FPKM value normalization and the average value of a gene for
each sample was plotted (Supplementary Figures 1B& 4). FollowingHAART, the total DEGs were 451 between the
HTI and HT groups (Supplementary Figure 1C). For distinguishing nonspecific DEGs from the specific ones, and
also considering that TB infection was an extra factor that requires stringent DEGs selection, the FPKM values of
the H group (before HAART) added in for K–W one-way significance test (with p-value < 0.01, FDR < 0.05) was
performed for HTI, HT, H groups together, in order to better understand the TB’s influence on gene expression.
There were 392 DEGs (197 up-regulated, 195 down-regulated, Figure 1C), which were DEGs among HTI, HT,
H groups that were used for pathway analysis (Supplementary Table 3). Similarly compared for intragroup, 88
DEGs were identified after HAART and were analyzed in a similar manner (Figure 1D, Supplementary Figure 4
& Supplementary Table 8).
Pathway analysis between HTI and HT groups was carried out using TargetMine [27] and in this analysis 38
of 392 DEGs were enriched in a significant pathway: the Generic Transcription Pathway (p-value = 1.11 ×10-6;
Supplementary Tables 3 & 4). Among the 38 genes, 30 (79%) of them were the zinc finger protein-coding genes.
Comparing the FPKM values in HTI, HT and H groups, respectively, for the ZNF genes, we found that the
expression level of 30 ZNF genes was considerably lower in the HTI group (p-value < 0.01, FDR < 0.05,
K–W test, Figure 2A) in comparison to the HT group. Following the qPCR analysis, we validated the consistent
expression trend of the ZNF genes (ZNF264, ZNF41, ZNF441) in the three groups, which was agreement with
the analysis of the FPKM values shown in Supplementary Figure 2. While we also noticed that after HAART,
ZNF genes described above did not show significant difference from that before HAART in the HTI or HT
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Figure 2. Expression levels of ZNF genes expression and its correlation with HIV-RNA load.
(A) Heatmap of 30 ZNF genes expression of Generic Transcription Pathway. High expression (red) gene and low expression (white) gene
determined by their FPKM values. (B) The Spearman correlation (r) of ZNF expression and log (HIV-RNA load). (C) Expression level of
several ZNF genes. The red and blue boxes separately represent the FPKM value before and after HAART. All are differentially expressed
among three groups before HAART (K–W test: p < 0.01; FDR < 0.05).
FDR: False discovery rate; FPKM: Fragments per kilobase million; HAART: Highly active antiretroviral therapy; K–W: Kruskal–Wallis.
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(A) Heatmap of 30 ZNF genes expression of Generic Transcription Pathway. High expression (red) gene and low expression (white) gene
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groups (Figure 2C & Supplementary Figure 3). Only ZNF225 in HT group and ZNF749 in HTI group showed a
significant difference before and after HAART (Rank test, p < 0.05), most of these ZNF genes were stable before
and after HAART (Supplementary Figures 2 & 3).
Functional domain analysis was conducted to see whether the extra unidentified ZNF proteins could share a
common domain and probably have the same function. The results showed that among 30 ZNF genes enriched
in Generic Transcription Pathway, 27 of them (except ZNF619, ZNF70 and ZNF71) belonged to Cys2His2 type
zinc finger protein with a Krueppel-associated box (KRAB) domain (Table 4). The C2H2-like fold group is by
far the best-characterized class of zinc fingers and is extremely common in mammalian transcription factors. The
number of zinc fingers in each ZNF protein varied from five to 19. Previous studies have pointed out that ZNF
genes with a KRAB domain can inhibit HIV proliferation; this matched the results of minus correlation coefficient
between HIV RNA load and FPKM of ZNF genes (before HAART). In this study, we have shown that the maximal
correlation coefficient was nearly up to -0.78 (ZNF559), and 19 of 26 ZNF genes were up to about -0.6, which
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Figure 3. I nterferon-stimulated genes pathway and genes expression level.
(A) Expression of IFN-induced genes in IFN-α/β-signaling pathway (from Reactome). Yellow boxes represent DEGs, which were found in
our data. (B) FPKM values of six genes enriched in the α/β-signaling pathway. The red and blue boxes separately represent the FPKM
values before and after HAART (K–W test in three groups, *p < 0.05, **p < 0.01; Wilcoxon Rank Sum Test in before/after,*p < 0.05,
**p < 0.01).
DEG: Differentially expressed gene; FPKM: Fragments per kilobase million; HAART: Highly active antiretroviral therapy; IFN: Interferon;
K–W: Kruskal–Wallis.
indicates the potentially negative correlation between ZNF genes expression level and HIV RNA load (Figure 2B
& Supplementary Table 5). Although three ZNF genes (ZNF70, ZNF619, ZNF71) with no KRAB domain also
showed little correlation with HIV load, the p-value was high (Supplementary Table 5). This further suggests that
the ZNF genes identified in our study may inhibit the proliferation of HIV to some extent, but functional studies
on how HIV is able to overcome this antiviral modality alone or in combination with mycobacteria with the
deteriorating immune system are sorely needed to cement this observation.
Interferon-stimulated genes like ISG15 were significantly expressed before HAART in the HTI group
For the comparison between before and after time points in the HT group, 36 DEGs were identified (28 up-
regulated, eight down-regulated), whereas for the comparison of HTI group (before and after HAART), 74 DEGs
were identified (50 up-regulated, 24 down-regulated). As we questioned why in some HIV patients IRIS occurs
after HAART, our subsequent analysis was focused on the comparison between before and after treatment time
points mainly in the HTI group. The DE genes before and after in the HT and the HTI groups were identified,
however, the number of overlapping genes between the two groups was only three (IFI44L, RSAD2, USP18) and
the expression pattern was greatly different in two groups (Figure 3B). For example, in the HT group, the gene
RSAD2 and USP18 were identified to be differentially expressed by Cuffdiff before and after HAART, while the
Wilcoxon Rank Sum Test result did not show significant difference. In contrast, both methods showed a significant
difference for the three genes before and after HAART for the HTI group. Furthermore, the fold-change of these
genes suggested that the downregulation before and after HAART was higher in the HTI group, as opposed to
both H and HT groups (Figure 3B).
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Finally, all these 72 DEGs derived from the HTI group were retained for pathway analysis using TargetMine. In
pathway analysis, nine of 72 DEGs (two genes were undefined, Supplementary Tables 6 & 7) from the HTI group
were significantly enriched in the IFN-α/β-signaling pathway (Figure 3A, p-value = 1.35 × 10-7, Holm-Bonferroni
[H-B] correction). Enriched genes were IFI6, IFITM1, IRF7, ISG15, MX1, MX2, OASL, RSAD2 and USP18,
respectively. Before HAART, FPKM values of several interferon-stimulated genes (ISGs; ISG15, IRF7 and MX2)
were substantially higher in the HTI group than in the H and HT groups (Figure 3B, K–W test). We also observed
that after the initiation of HAART treatment, the FPKM values of IFI6, IFITM1, IRF7, ISG15, MX1, OASL
decreased sharply [32] (Figure 3B, p-value < 0.05, Wilcoxon Rank Sum test).
Other pathways that were significantly enriched by TargetMine were in the cytokine-related pathways (Sup-
plementary Table 8), such as cytokine signaling in immune system (p-value = 1.1 ×10-3, H-B correction) and
cytokine–cytokine receptor interaction (p-value = 1.9 ×10-2, H-B correction). After the initiation of HAART, the
expression level of genes enriched in these pathways was relatively higher than in the before therapy group, which
was consistent with the previous microarray-based study [18,33].
The GSEA [30] for the H, HT and HTI groups showed that 29 (nine up-regulated), 26 (15 up-regulated) and
nine (eight up-regulated) DEG sets changed in all three groups following HAART (Supplementary Table 9), and
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in the groups H and HT, a higher overlap was observed for both up- and down-regulated gene sets (nine up and
nine down), a reflection of which could be seen in the PCA (Figure 1B). Among the down-regulated gene sets, all
three groups shared the IFN-α/β-signaling gene sets with a different Normalized Enrichment Score (HTI = -2.5,
HT = -1.97, H = -2.16), which showed significant decrease particularly in the HTI group and concurred with the
results of pathway analysis (Figure 3A & B). Among the nine down-regulated overlapping gene sets in the H and
HT groups, we found some gene sets related to cell cycle and mitosis, such as G2/M checkpoints and cell cycle
mitotic activity. Previous studies have shown that HIV-type 1 vpr gene could arrest infected T cells in the G2/M
phase of the cell cycle [34]. HIV LTR has high activity in the G2 phase of the cell cycle for its own benefit. After
the initiation of HAART, these gene sets related to cell cycle were significantly down-regulated, which revealed a
positive effect of HAART in both H and HT groups. Besides, we also observed that gene sets related to protein
synthesis were up-regulated to varying degrees, such as 3-UTR-mediated translational regulation and peptide chain
elongation in the H and HT groups, whereas transport to the Golgi and subsequent modification and transport of
mature mRNA derived from an intron less transcript in the HTI group. Although the gene sets did not overlap
between H/HT and HTI groups, they indirectly showed enhancement in the protein synthesis activity following
the initiation of HAART suggesting reconstitution of the immune system.
We also found 451 genes were differentially expressed after HAART between HT and HTI groups (Supple-
mentary Figure 1C). With FPKM value of H group added in, K–W one-way significance test was performed to
select out the final 88 significant DEGs (seven down-regulated, 81 up-regulated in the HTI group, Figure 1D,
Supplementary Table 10). Pathway analysis-enriched genes in cell cycle, mitosis and cell cycle checkpoint-related
pathways, and all these genes were down-regulated in the HT group when compared against the HTI group
(Supplementary Table 11), which was consistent with the GSEA results.
The potential difference in the TB content between HTI & HT groups
Using the 392 DEGs identified in the pathway analysis for GO (gene ontology) enrichment in biological process by
TargetMine (p < 0.05, H-B correction), the most significant GO was rooted in the defense response to bacterium
(Figure 4A). Sixteen genes enriched in this pathway segregated the HTI, HT and H groups based on expression
profiles. We observed that except for the TLR9 gene in the HTI group, the expression levels of other genes were
significantly higher than the other two groups (p < 0.01, K–W test). Among these genes, the S100A8/S100A9
genes, also called MRP8/14 (Figure 4B), coding for calprotectin (a heterodimer of two calcium-binding proteins
present in the cytoplasm of neutrophils and expressed on the membrane of monocytes [35]) were observed. Other
relatively significant GO terms were also related to RNA synthesis and transcription, similar to the results of
Pathway Enrichment mentioned above, which occurred at the initiation of HAART suggesting some genomic
difference at the transcriptional level between HT and HTI groups.
Marais et al. have shown that 2 weeks after the initiation of ART, compared with MTB non-IRIS patients,
S100A8/S100A9 was significantly increased in TBM (tuberculous meningitis)-IRIS patients [15]. Together with
our findings on the expression level of S100A8/S100A9, the expression of these two genes was also higher in the
HTI group, and it also increased following HAART.
Discussion
This study shows a systematic deep-sequencing transcriptomic analysis, using RNA-seq technology, of the TB-IRIS
patients and shows the possible genomic basis of it. We found that ZNFs and ISGs were intrinsically involved
in TB-IRIS. To explain the intrinsic association between ISGs and ZNF genes, it is worthy of mentioning that
the ISGs demonstrated a synergistic antiviral activity with zinc-finger antiviral protein (ZAP), and multiple ISGs
synergize with the ZAP to mediate anti-alphavirus activity [36]. We believe this could be one explanation for our
observations, as both ISGs and zinc-finger gene enrichment was seen in our data, yet it is difficult to determine
how each of the ISGs and ZNF genes synergize and recover following HAART to maintain intrinsic association
between them in countering HIV and Mycobacterial infection in the face of deteriorating immune system. Many
ISGs play function more antiviral effectively in the presence of zinc finger that suggests in addition to possible
direct interactions with the individual ISGs, ZNF genes function by altering the intracellular milieu in a manner.
But whether the seamless communication between ISGs and ZNF remains intact upon the development of IRIS is
reflected in the unique genes in cellular processes guiding the cellular integrity that we observed in the HTI group.
In respect toZNF genes, it is noteworthy that previous studies have revealed that someZNFproteins (i.e., ZNF10,
ZNF175 [37,38]) could effectively inhibit the proliferation of HIV through the interaction with NF-κB and Sp1-
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binding motifs [39], and the ZAP could inhibit HIV-1 by recruiting both the 5′- and 3′-mRNA degradation
machinery to specifically degrade multiply spliced HIV-1 mRNAs [40]. Yet other studies have shown that ZNF
proteins (hZNF 134) could, on the contrary, promote HIV replication [41]. In our analysis of the ZNF genes
identified, the motif of ZNF175 (or OTK18) overlapped with this study that showed the motif functionally to
inhibit HIV replication. Although the expression of ZNF genes is strongly functionally correlated, the function
of other ZNF genes identified in our study remains to be elucidated [42]. Supporting this argument, recently
the hZNF134 has been shown to promote viral replication during coinfection with HIV and Mycobacteria [22].
Although hZNF134 was not observed in our study, it does suggest a similar modality taking place during the
infection process with other ZNF genes we have found enriched, and whose roles remain unclear.
Furthermore, to put this in the context of ZNF synergy with the ISGs, we found significant correlation between
before and after HAART functional expression levels of ISGs in the HIV-TB-IRIS group, which decreased sharply
in contrast to the H and HT groups, where the expression levels were maintained at lower levels. Supporting this,
there was concomitant decline in the gene expression of ZNFs in the HTI group, which also showed considerable
variability pre- and post-HAART. Thus, despite the enrichment of ISGs and ZNFs, this lack of synergy could be a
consequence of their declining expression in the HTI group coupled with the immunological imbalance between
them, in which HAART fails to restore in the face of crumbling immune system. Alternatively, it is likely that
ISGs go up and ZNFs decline means that ZNFs no longer leave the cells permissible to ISG function. In the light
of these observations, the involvement of Mycobacterium infection, accompanied by considerable deterioration of
the immune system and factors that govern cellular integrity, which is reflected in imperfect recovery in patients’
CD4+ T-cell counts and plasma viremia following HAART. Thus, the imbalance and diminishing trends of both
ZNFs and ISGs after HAART could act as vital factors in determining the effectiveness of the seamless synergy
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ZNF and ISGs maintain in a healthy immune system. To reinforce this idea, previous studies have pointed out
that ISG15 gene could inhibit the release of HIV from cells [43] and IFITM1 [44] gene inhibits viral replication
and proliferation [45] and also affects the expression levels of IRF7, MX2, OAS1, which are associated with CD4+
T-cell count and plasma HIV viral load [46]. These were among the nine significant ISGs identified in our study,
cementing their functional significance.
Thus, looking into the nature of genes that makes the HTI group unique, we found that this was guided by
the genes that govern cellular integrity related to DNA, chromosome, microtubule, leukocyte migration, actin, cell
adhesion and proliferation, and so forth. In light of these observations, we hypothesize that the integrity of cellular
processes may be impaired in the HTI group, and may possibly associate with IRIS, along with the loss of synergy
between ISGs and ZNFs.
Based on the commonly accepted notion that there are no ‘signature genes’ in the CD4+ cells [47], in our data
also, there was no significant correlation between CD4+ T-cell number and most (38/38 in H group, 37/38 in
HT group, 34/38 in HTI group) ZNF DEGs (38 ZNF DEGs that enriched in Generic Transcription Pathway,
Supplementary Table 4). Up- or downregulations of these ZNF genes mentioned above did not follow the increase
of CD4+ T-cell numbers in different patients, suggesting that the Generic Transcription Pathway was truly the
difference.
Another feature of our study was the high expression of S100A8/S100A9 genes in theHTI group beforeHAART.
Both pro- and anti-inflammatory properties reported for these proteins are involved in activating TLR4 responses.
It functions by binding the receptors (RAGE, TLR4) in the membrane, activating and mediating the inflammatory
signaling pathway and biological process. S100A8 and S100A9 can function separately, likely through distinct
receptors but a systematic comparison of their effects in vivo is limited. Previous studies have shown that the
S100A8 protein has a regulatory effect in inflammatory signal transduction. In vitro proinflammatory factors, such
as LPS, TNF and IL-1 could induce S100A8 expression in macrophages and endothelial cells [48–50]. S100A8
could stimulate inflammatory cells to release factors, directly get involved in the inflammatory process [51]. Other
studies have also revealed that S100A8 protein can help treat traumatic inflammation [52]. In vitro S100A8/S100A9
could nonspecifically bind cytokines like IL-1β, IL-6 and TNF-α. Moreover, it can also inhibit expression of
some inflammatory cytokines at the gene level [53]. In our data, after HAART, no significant upregulation of
S100A8/S100A9 gene was noticed, but an upregulation of an anti-inflammatory cytokine (IL-10) and a series
of receptors (IL7R, CCR4, Supplementary Table 8) after HAART was observed, which possibly resulted in
immunological imbalance, and may be one of the reasons for the development of TB-IRIS. It is to be noted that
S100A8 induction is IL-10 dependent [54], regulated in a manner similar to the IL-10 gene, but S100A9 has no
effect on this, suggesting that these genes also work separately in governing the pro- and anti-inflammatory cytokine
expression.
Furthermore, it is important to iterate that previous studies have shown that patients with active TB had
significantly increased plasma levels of calprotectin compared with pulmonary sarcoidosis and healthy controls [35].
Supporting this, it has also been shown that it augments MTB growth in a dose- and time-dependent manner [55].
Schwartz et al. have shown that in HIV disease, dysregulated neutrophil responses to endotoxins stimulation and
S100A8/A9 inhibition may contribute to a higher risk for oxidative stress-associated ailments [56]. Then, elevated
serum levels of S100A8, S100A9 and their heterocomplex calprotectin have been reported in association with HIV
infection, especially during disease exacerbation [57].
Based on our observations, higher expression levels of S100A8/S100A9 in the IRIS (HTI group) tend to favor TB
infection and replication, suggesting that after anti-TB therapy, an inconspicuous state of a more severe infection
of TB exists in the HTI group that TB-IRIS arises from a combination of a high MTB antigen load at ART
initiation [3] and differential antigen recognition and immune signaling by innate immune receptors after ART
initiation in TB-IRIS patients, which in turn contributes to hypercytokinemia and inflammation. We believe
this could be a hidden factor for the breakaway of IRIS after HAART. Whether increased S100A8/A9 levels in
association with inflammation or infection, contribute to enhanced immune response as suggested by some [58] or
instead, represent a native anti-inflammatory process as suggested by others [59] remain to be fully elucidated.
In light of these observations, we hypothesize one of possible mechanistic models for the occurrence of IRIS
(Figure 5). Before HAART, among the HIV-TB-coinfected patients, low expression levels of ZNF genes were
observed. It is notable that some ZNF-encoded proteins show the ability to inhibit HIV proliferation. But due
to some self- and cellular integrity defects coupled with weaker synergy between ISGs and zinc finger genes in
mounting antiviral effect may impair this inhibitory activity, causing higher HIV RNA load in the blood and
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poor sequestration of immune cells and imperfect control of viremia. Thus, for these patients, their relatively low
immunity with less CD4+ T-cell could not effectively attack the Mycobacterium existing in their bodies due to
excessive HIV load possibly stimulating expression of ISGs (i.e., ISG15) [46,60], causing them to overexpress in
order to compensate for the low expression of ZNF genes.
After the initiation of HAART, the HIV RNA load decreased and the expression of ISG15 gene also declined,
which is consistent with a recent study of time points before and after HAART in HIV patients [61]. Researches have
pointed out that ISG15 gene had the anti-inflammatory effect, and low expression of ISG15 gene could cause low-
level USP18, triggering the generation of type I IFN and increase of the signal function and prompt the occurrence
of autoinflammation [62]. A recent study of cytokine in the HTI patient group showed that following the initiation
of HAART, cytokines and proinflammatory factors were up-regulated, which could promote autoinflammation [33].
The excessive immune response together with the inflammation further exacerbated the reaction of IRIS. Moreover,
the inflammation that affects the regulative ability and the expression of S100A8/S100A9 may act as a contributory
factor for the development of IRIS in HIV/TB patients.
Marais et al. have shown that 2 weeks after the initiation of ART, a high baseline MTB antigen load drives an
inflammatory response that manifests clinically as TBM-IRIS in most, but not all, patients with TBM. Neutrophils
and their mediators, especially S100A8/A9, are closely associated with the central nervous system inflammation
that characterizes TBM-IRIS [15]. Thus, together with our findings on the expression level of S100A8/S100A9, we
believe that for the HIV/TB coinfection patients, higher expression level of S100A8/S100A9 appears to favor TB
infection, replication and occurrence of TB-IRIS.
Conclusion
Our result is showing the possible genomic basis of TB-IRIS, which revealed that genes of ZNF and interferon-
stimulating families were important in the inhibition of HIV replication. Through their expression in the three
groups, we were able to visualize functional synergies that evolve differently as the immune system deteriorates.
These findings have laid a foundation for the gene expression levels to be used as a classifier for predisposition to
TB-IRIS, but more data are needed on larger number of patients. While the expression of ZNF genes may be an
important factor for AIDS patients for defining the initiation time of HAART, their synergy with the ISGs is of
paramount importance in mounting an antiviral effect and maintenance of the immune system during HAART, as
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its antiviral activity heavily relies on the health of the immune system. These data propose a possible pathogenetic
mechanism and show the first snapshot of the genomic basis of TB-IRIS, which may lay a strong foundation for
the development of new generation of genomic biomarkers leading to better treatment strategies for HIV-TB-IRIS.
Summary points
• There is possible genomic basis of TB-immune reconstitution inflammatory syndrome (IRIS) which revealed that
genes of ZNF and interferon-stimulating families were important in the inhibition of HIV replication.
• Significant differential lower expression of ZNF genes in TB-IRIS groups regardless of before or after highly active
antiretroviral therapy (HAART) although it changed little after HAART.
• There is negative relationship between ZNF genes’ expression and HIV virus load before HAART in all groups
before HAART.
• The differentially expressed ZNF genes which with a Krueppel-associated box domain enriched in Generic
Transcription Pathway.
• Interferon-stimulated genes like ISG15 were significantly higher expressed before HAART in the HIV-TB+ with IRIS
group but dropped quickly after HAART.
• For the differentially expressed genes between IRIS and non-IRIS groups, the most significant GO enrichment was
rooted in the defense response to bacterium.
• The TB-associated gene S100A8/S100A9 is expressed higher in TB-IRIS group before HAART, which leads the
potential IRIS development.
• There is a possible pathogenetic mechanism and shows the first snapshot of the genomic basis of TB-IRIS, which
may lay a strong foundation for the development of new generation of genomic biomarkers leading to better
treatment strategies for HIV-TB-IRIS.
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